In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer’s fully integrated $20 billion healthcare business
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
The company has secured 506 marketing approvals for its oncology products across 76 countries.
Good momentum in commercial CDMO business
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Subscribe To Our Newsletter & Stay Updated
